Primary care physician versus urologist: How does their medical management of LUTS associated with BPH differ?

Current Urology Reports

Volumn 10, Issue 4, 2009, Pages 254-260

  Miner, Martin M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATININE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; CYSTOSCOPY; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DISEASE REGISTRY; DISEASE SURVEILLANCE; DIZZINESS; EJACULATION DISORDER; EVALUATION; FATIGUE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; IMPOTENCE; LIBIDO; LOWER URINARY TRACT SYMPTOM; MEDICAL SPECIALIST; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PHYSICIAN; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RESIDUAL URINE; REVIEW; SEXUAL FUNCTION; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; URINALYSIS; UROFLOWMETRY; UROLOGY; WATCHFUL WAITING;

ALGORITHMS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE; PROSTATIC HYPERPLASIA; PROSTATISM; UROLOGY;

EID: 68149091820     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-009-0042-7     Document Type: Review

References (28)

1. Margolis S, Carter HB: Prostate disorders. In The Johns Hopkins White Paper. Baltimore: Johns Hopkins Medicine; 2002.
2. H. Lepor 2004 Challenges in the detection and diagnosis of bladder dysfunction: optimal strategies for the primary care physician Rev Urol 6 Suppl1 S1 S2
3. J.D. [tmp] McConnell C.G. Roehrborn O.M. Bautista 2003 The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2387 2398 (Pubitemid 37542987)
4. J. Barkin M. Guimarães G. Jacobi 2003 Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha-reductase inhibitor dutasteride Eur Urol 44 461 466 (Pubitemid 37185673)
5. J.M. Fitzpatrick 2005 Should combination therapy be standard for benign prostatic hyperplasia? Nat Clin Pract Urol 2 574 575 (Pubitemid 43135235)
6. C.G. Roehrborn P. Siami J. Barkin 2008 The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study J Urol 179 616 621
7. Steers WD, Nuckolls J, Seftel AD, et al.: Differences between PCPs and urologists in the evaluation of men with LUTS/BPH [abstract 6]. Presented at the American Urological Association 2006 Annual Meeting. Atlanta, Georgia; May 20-25, 2006.
8. Wei JT, Nuckolls J, Miner M, et al.: Differences in medical management of LUTS/BPH between PCPs and urologists [abstract 7]. Presented at the American Urological Association 2006 Annual Meeting. Atlanta, Georgia; May 20-25, 2006.
9. C.G. Roehrborn J.D. [tmp] McConnell M. Lieber 1999 Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group Urology 53 473 480 (Pubitemid 29136187)
10. L. Kuritzky 2003 A primary care physician's perspective on benign prostatic hyperplasia Rev Urol 5 Suppl5 S42 S48
11. M.J. Naslund F.J. Costa M.M. Miner 2006 Managing enlarged prostate in primary care Int J Clin Pract 60 1609 1615 (Pubitemid 44742161)
12. B. Djavan Y.K. Fong M. Harik 2004 Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years Urology 64 1144 1148 (Pubitemid 39647056)
13. P. Boyle C.G. Roehrborn R. Harkaway 2004 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery Eur Urol 45 620 627 (Pubitemid 38481690)
14. J.D. [tmp] McConnell R. Bruskewitz P. Walsh 1998 The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group N Engl J Med 338 557 563
15. C.G. Roehrborn P. Boyle J.C. Nickel 2002 Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 431 434
16. C.G. Roehrborn L.S. Marks T. Fenter 2004 Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia Urology 63 709 715 (Pubitemid 38479415)
17. G. Andriole N. Bruchovsky L.W. Chung 2004 Dihydrotestosterone and the prostate: the scientific rationale for 5-alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia J Urol 172 4Pt1 1399 1403 (Pubitemid 39249729)
18. S.A. Kaplan 2004 Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual functioning Urology 63 428 434
19. H. Lepor 1995 Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group Urology 45 406 413
20. H. Lepor 1998 Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group Urology 51 892 900 (Pubitemid 28240845)
21. P. Narayan A. Tewari 1998 A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia J Urol 160 1701 1706 (Pubitemid 128746741)
22. C.G. Roehrborn 2001 Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Alfus Study Group Urology 58 953 959 (Pubitemid 34017278)
23. AUA Practice Guidelines Committee 2003 AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations J Urol 170 2Pt1 530 537
24. E.J. Wright J. Fang E.J. Metter 2002 Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging J Urol 167 2482 2488
25. C.G. Roehrborn 2006 Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia, but not acute urinary retention: results of a 2-year placebocontrolled study BJU Int 97 734 741 (Pubitemid 43383505)
26. M. Miner M.T. Rosenberg M.A. Perelman 2006 Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function Clin Ther 28 13 25 (Pubitemid 43254986)
27. R. Rosen J. Altwein P. Boyle 2003 Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7) Eur Urol 44 637 649 (Pubitemid 37542920)
28. P. Siami C.G. Roehrborn J. Barkin 2007 Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design Contemp Clin Trials 28 770 779 (Pubitemid 47499255)